Three Semaglutide Recalls in One Month: Inside the Generic GLP-1 Quality Failures

In a single month, Health Canada published three separate recalls of generic semaglutide injection, a generic version of the diabetes medicine Ozempic. Two manufacturers were involved, ten lots were named across the three recalls, and each recall pointed to a different quality failure. One pen could deliver the wrong dose. One product carried an impurity that was out of specification in every lot. One carton held a pen of the wrong strength. Taken together, they are a compact lesson in how generic injectable quality can break down, and in what a quality team must build to prevent it.

Generic GLP-1 medicines are among the fastest growing categories in the Canadian market. Apotex received Health Canada approval for the first Canadian generic equivalent of Ozempic on 1 May 2026 and launched it days later, and other entrants have followed. That surge in supply is good news for patients and payers, but it puts new pressure on quality systems that have to be right the first time. A semaglutide pen is not a simple vial. It is a drug-device combination product, where a dosing error can come from the medicine, the device, or the packaging line. These recalls involve commercially manufactured generic products, not the compounded preparations we examined in our review of FDA's compounded GLP-1 warning letters, which raise a different set of risks. This article walks through each recall, maps it to the control that should have caught it, and gives generic injectable teams a practical checklist.

Executive summary

Between 12 and 27 August 2026, Health Canada classified three semaglutide injection recalls as Type II, meaning the product may cause temporary harm or the chance of serious harm is remote. The three failures were a pen that could display and deliver 2 mg instead of the intended 0.25 mg or 0.5 mg starting dose (Apotex), an impurity out of specification in all lots (Dr. Reddy's), and a carton labelled as 2 mg per pen that actually held a 4 mg pen (Dr. Reddy's). No single root cause explains all three. They span device design and human factors, specification and stability control, and packaging line clearance. That breadth is the point: a mature generic injectable quality system has to defend on all three fronts at once.

• Three Type II recalls, two manufacturers, one drug class, three different root-cause families, all within one month.
• A semaglutide pen is a drug-device combination product, so dose accuracy depends on the medicine and the device together.
• An impurity out of specification in every lot points to a specification, stability or supplier problem, not a one-off deviation.
• A wrong-strength pen in a labelled carton is a packaging line-clearance and reconciliation failure.
• The disciplines that prevent these recalls, design verification, out-of-specification investigation and line clearance, are all auditable long before a product ships.

What happened: three recalls in one month

What is the story? Health Canada published three Type II recalls of generic semaglutide injection between 12 and 27 August 2026. Two makers, Apotex and Dr. Reddy's, were involved, and each recall names a different defect. The table below sets them side by side.

All three were classified Type II and set at a depth of recall of retailers, which means the affected product was being pulled back from pharmacies and distributors rather than only from a central warehouse. None of the three was a cosmetic issue. Each one could change the dose a patient receives or expose them to an impurity, which is why dose-accuracy defects in this class deserve close attention. Firms and pharmacists should verify affected lots against the Health Canada notices linked at the end of this article. The Apotex notice even carries a lot-number correction in its change log, a useful reminder that recall records themselves get revised and should be checked at source.

Recall one: a pen that could deliver the wrong dose

What went wrong? Apotex recalled one lot of Apo-Semaglutide Injection (RA-82536) because the affected pen may display a 2 mg dose in the dose window and deliver 2 mg, instead of the expected 0.25 mg or 0.5 mg dose. For a patient starting therapy, that is roughly four to eight times the intended dose.

Semaglutide is deliberately started low and increased slowly. A common schedule begins at 0.25 mg once weekly for four weeks, an initiation dose that is not meant to control blood sugar on its own, then steps up to 0.5 mg, and only later to higher maintenance doses. The slow escalation exists to limit gastrointestinal side effects. A pen that jumps a first-time patient straight to 2 mg defeats that safety design.

This is a device and human-factors failure as much as a drug failure. The dose is selected on the pen, shown in a dose window, and delivered by an injection mechanism. If the window can show one number while the mechanism delivers another, then the design verification, the tolerance analysis of the dose-setting mechanism, and the human-factors validation of the display all deserve scrutiny. Health Canada regulates a pre-filled pen like this as a drug-device combination product, so the device constituent must meet acceptable standards of quality even though the whole product is approved as a drug. Teams building or reviewing these products should treat the dose-setting mechanism as a critical-to-quality feature, with documented design verification and use-related risk analysis. Our guide to FDA human factors submission categories explains how usability evidence is structured, and the principles carry across to Canadian combination products.

Recall two: an impurity out of specification in every lot

What went wrong? Dr. Reddy's recalled two market authorizations of Semaglutide Injection (RA-82537) because an impurity was out of specification in all lots of the affected products. Eight lots across two drug identification numbers were named. An out-of-specification result in a single lot is a deviation. The same result in every lot is a signal about the product, its specification, or its supply chain.

An out-of-specification, or OOS, result means a test result falls outside the registered acceptance criteria. When it appears in one lot, a laboratory investigation asks first whether the result is real or a testing error, then whether the batch can be released. When the same impurity is out of specification across every lot, the investigation has to look upstream. Possible causes include an active ingredient or starting material carrying a higher impurity load than was qualified, a degradation pathway the stability programme did not fully predict, a specification set without the right method to support it, or a change at the drug-substance supplier that was not properly assessed. The Canadian market authorization is held by Dr. Reddy's Laboratories Ltd in India, which puts the spotlight on supplier qualification and imported-product oversight.

For a quality team, the discipline is the same one regulators cite first when they inspect: a thorough, timely, scientifically sound investigation. Our detailed walkthrough of 21 CFR 211.192 batch-failure investigations sets out how to separate laboratory error from a true result, extend the review to other lots, and decide on disposition with a documented rationale. Impurity control also depends on a stability programme that can detect a rising degradant before it reaches the limit, and on qualifying every impurity to a recognized threshold. When a foreign site supplies the Canadian market, the importer's quality agreement and audit programme carry real weight.

Recall three: a 4 mg pen in a 2 mg carton

What went wrong? Dr. Reddy's recalled one lot of Semaglutide Injection (RA-82477) because a carton labelled as 2 mg per pen actually contained a 4 mg pen. The medicine was correct. The strength in the box did not match the label. That is a packaging and labelling control failure, and specifically a line-clearance failure.

Packaging lines often run more than one strength of the same product on the same equipment on different days. Line clearance is the formal check that removes all materials from the previous run, components, printed cartons, leaflets and product, before the next run begins, and reconciles what was issued against what was used and what remains. A single stray pen from a 4 mg run that survives into a 2 mg run is exactly the defect line clearance exists to prevent. Reconciliation of components and finished units is the second net: if the counts do not balance, the batch should not be released until the discrepancy is explained.

We examined this control in detail after a 2026 kit recall, and the lessons transfer directly to pen assembly and cartoning. Our article on packaging line clearance describes the checks, the documentation, and the common gaps inspectors find. For pens, the risk is heightened because the outer carton is often the only place the strength is stated in a way the patient reads. When the label and the contents disagree, the safeguards inside the pharmacy and the home cannot catch it.

Why a combination product raises the stakes

What is a drug-device combination product? It is a therapeutic product that integrates a drug and a device in a single item, such as a pre-filled injection pen. In Canada, the product is classified by its principal mechanism of action. Because semaglutide works pharmacologically, the pen is regulated as a drug under the Food and Drug Regulations, yet the device constituent must still meet acceptable standards of quality.

Health Canada's policy on combination products states that both the principal and the ancillary components must meet acceptable standards of safety, efficacy and quality, even though the whole product is regulated under one set of regulations. In practice, a generic pen has to satisfy drug expectations, active ingredient identity and purity, stability and sterility, and device expectations, dose accuracy, mechanical reliability and safe use, at the same time. Two of the three recalls in this cluster, the wrong-dose pen and the wrong-strength pen, are failures at that drug-device seam. Many generic entrants underestimate this work. A company with strong small-molecule chemistry may treat the pen as packaging rather than as a device with its own design controls, verification testing and use-related risk file. When a device constituent fails, the recall is reported through the drug pathway, but the fix lives in device engineering. Teams that want to see how device-side reporting works can review our explainer on medical device recall reporting in Canada, which sets out the 24-hour clock and what counts as a reportable recall.

What a Type II recall means in Canada

Why does the recall class matter? Health Canada assigns every health-product recall a class. A Type II recall covers a situation where use of the product may cause temporary adverse health consequences, or where the probability of serious harm is remote. All three semaglutide recalls were Type II. That classification shapes how fast the recall moves and how far down the supply chain it reaches.

Under Health Canada's recall guide, a Type I recall is the most serious, used where there is a reasonable probability of serious harm or death. Type II sits below it, and Type III covers products unlikely to cause any harm. A dose-accuracy defect can sit near that boundary, which is why classification, the health-hazard evaluation and the depth of recall are decisions a quality team should be ready to defend. Being able to run a fast, well-documented recall, including a health-hazard assessment and a reconciliation of distributed units, is part of inspection readiness. A mock recall, tested in advance, is the cheapest way to find the gaps before an inspector or a real event does.

Compliance checklist for generic injectable and GLP-1 quality

Use this checklist to pressure-test a generic injectable or pen programme before a defect becomes a recall.

• Treat the dose-setting mechanism and dose window as critical-to-quality features, with documented design verification and tolerance analysis.
• Complete use-related risk analysis and human-factors validation for the pen, including the display and the dose-selection steps.
• Qualify every impurity to a recognized threshold and confirm the analytical method can detect it reliably.
• Run a stability programme designed to flag a rising degradant before it reaches the specification limit.
• Qualify each active ingredient and starting-material supplier, with a quality agreement and an audit schedule, especially for foreign sites.
• Investigate every out-of-specification result promptly and extend the review to other lots when a systemic cause is possible.
• Enforce packaging line clearance between strengths, with documented removal of all prior materials and product.
• Reconcile components and finished units at the end of every packaging run, and hold release until the counts balance.
• Keep a current health-hazard evaluation and recall procedure, and test them with a mock recall.
• Define importer and market authorization holder responsibilities clearly when a foreign site manufactures the product.

Common mistakes

• Treating the pen as packaging. Assuming a pre-filled pen is packaging rather than a device leaves the dose-setting mechanism without real design controls.
• Closing an OOS as laboratory error too quickly. Ending an investigation at the bench misses a systemic impurity, stability or supplier cause.
• Setting specifications without the method to support them. A limit is only as good as the analytical method that measures it.
• Running strengths back to back without hard line clearance. Shared lines and similar cartons are where a wrong-strength pen slips through.
• Under-resourcing oversight of foreign sites. A distant drug-substance supplier still needs qualification, a quality agreement and audits.
• Discovering the recall procedure during the recall. A first-time health-hazard evaluation under time pressure is how classification and depth go wrong.

Frequently asked questions

Why were the generic semaglutide products recalled in Canada?

Health Canada published three Type II recalls in August 2026. Apotex recalled a lot of Apo-Semaglutide Injection because a pen could display and deliver 2 mg instead of the intended 0.25 mg or 0.5 mg. Dr. Reddy's recalled products because an impurity was out of specification in all lots, and separately because a carton held a 4 mg pen but was labelled 2 mg. Each recall is described on the Health Canada notices linked below.

What does incorrect dose display mean on a semaglutide pen?

It means the number shown in the pen's dose window did not match the dose the pen delivered. In the Apotex recall, the affected pen could show and deliver a 2 mg dose when the patient expected 0.25 mg or 0.5 mg. Because semaglutide is started at a low dose and increased slowly, a jump to 2 mg is a significant overdose for someone beginning treatment.

What is an out-of-specification impurity recall?

An out-of-specification, or OOS, result is a test result that falls outside the product's registered acceptance criteria. An OOS impurity recall happens when an impurity exceeds its limit. When the impurity is out of specification in every lot, as in the Dr. Reddy's recall, the cause is usually systemic: the specification, the analytical method, the stability behaviour, or the drug-substance supply, rather than a single testing error.

Is generic semaglutide safe to use?

Generic semaglutide approved by Health Canada is held to the same standards as the reference product when it is manufactured correctly. These recalls involve specific lots with specific defects, not the whole product class. Patients should check whether their lot is affected using the Health Canada notices and should speak with their healthcare provider before stopping any medicine. This article is written for industry and is not medical advice.

How is a semaglutide pen regulated in Canada?

A pre-filled semaglutide pen is a drug-device combination product. Health Canada classifies combination products by their principal mechanism of action. Because semaglutide acts pharmacologically, the pen is regulated as a drug under the Food and Drug Regulations, while the device constituent must still meet acceptable standards of quality. That dual expectation is why dose accuracy and mechanical reliability matter as much as chemistry.

What is the difference between a Type I, Type II and Type III recall in Canada?

Health Canada classifies recalls by the health risk. A Type I recall is used where there is a reasonable probability of serious harm or death. A Type II recall covers products that may cause temporary harm or where the chance of serious harm is remote. A Type III recall applies to products unlikely to cause harm. All three semaglutide recalls were Type II.

How MFLRC can help

MF License and Regulatory Consultants helps generic and specialty manufacturers build the quality systems that keep a dose-accuracy defect from becoming a recall. For pen and injectable programmes, we run gap assessments against Health Canada and international expectations, develop the SOPs and the design-verification and human-factors documentation for the device constituent, and structure out-of-specification and stability programmes that hold up under inspection. Our quality control and pharmaceutical validation teams support method and process validation, and our audit team runs supplier and mock-recall audits so you find the gaps before an inspector does. We work across the full lifecycle, from licensing and import and export compliance to post-market recall management, for companies entering the Canadian pharmaceutical market.

Conclusion

Three recalls in one month, from two manufacturers, in the most talked-about drug class in years, is not a coincidence. It is what happens when supply scales faster than quality systems mature. The failures were not exotic. A dose mechanism, an impurity specification, and a packaging line are the ordinary machinery of pharmaceutical quality. Each was preventable with controls that can be built, documented and audited in advance. For any company bringing a generic injectable or GLP-1 product to Canada, the message is simple: design the dose to be right, prove the impurity is controlled, and clear the line every time. The rest is discipline.

Sources and references

• Health Canada, Apo-Semaglutide Injection: Incorrect dose display (RA-82536).
• Health Canada, Semaglutide Injection: Out-of-Specification (Impurity) (RA-82537).
• Health Canada, Semaglutide Injection: Incorrect Pen in Package (RA-82477).
• Health Canada, Drug, natural health product and biocide recall guide (GUI-0039).
• Health Canada, Policy on Drug/Medical Device Combination Products.
• US FDA, 21 CFR 211.192, investigation of production discrepancies, via eCFR.